Search research articles
Contact Us
Filters
Showing results (181-190 of 215) with videos related to
Page
of 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
Joyce F Liu, Mark F Brady, Ursula A Matulonis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 20, 2022
Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Min Liu, Nabihah Tayob, Livius Penter, et al.
Science (New York, N.Y.)
|
October 29, 2011
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy
Triona Ni Chonghaile, Kristopher A Sarosiek, Thanh-Trang Vo, et al.
Gynecologic Oncology
|
October 20, 2023
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
Jonathan A Ledermann, Ronnie Shapira-Frommer, Alessandro D Santin, et al.
Gynecologic Oncology
|
May 17, 2024
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib
Joyce F Liu, Niya Xiong, Robert M Wenham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 29, 2019
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer
Panagiotis A Konstantinopoulos, Weixiu Luo, Joyce F Liu, et al.
Cancer Discovery
|
September 15, 2018
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Sarah J Hill, Brennan Decker, Emma A Roberts, et al.
British Journal of Cancer
|
December 10, 2021
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Jeffrey G Supko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 31, 2016
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics
Joyce F Liu, Sangeetha Palakurthi, Qing Zeng, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists
|
May 12, 2018
Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC)
Helena M Ditzel, Kyle C Strickland, Emily E Meserve, et al.
Page
of 22
Search research articles
Search
Showing results (181-190 of 215) with videos related to
Sort By:
Page
of 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
Joyce F Liu, Mark F Brady, Ursula A Matulonis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 20, 2022
Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Min Liu, Nabihah Tayob, Livius Penter, et al.
Science (New York, N.Y.)
|
October 29, 2011
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy
Triona Ni Chonghaile, Kristopher A Sarosiek, Thanh-Trang Vo, et al.
Gynecologic Oncology
|
October 20, 2023
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
Jonathan A Ledermann, Ronnie Shapira-Frommer, Alessandro D Santin, et al.
Gynecologic Oncology
|
May 17, 2024
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib
Joyce F Liu, Niya Xiong, Robert M Wenham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 29, 2019
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer
Panagiotis A Konstantinopoulos, Weixiu Luo, Joyce F Liu, et al.
Cancer Discovery
|
September 15, 2018
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Sarah J Hill, Brennan Decker, Emma A Roberts, et al.
British Journal of Cancer
|
December 10, 2021
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Jeffrey G Supko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 31, 2016
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics
Joyce F Liu, Sangeetha Palakurthi, Qing Zeng, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists
|
May 12, 2018
Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC)
Helena M Ditzel, Kyle C Strickland, Emily E Meserve, et al.
Page
of 22